Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06481943 · ClinicalTrials.gov registry record
A Prospective Research Investigation of Ischemia Using MCG
A clinical trial of Acute Coronary Syndrome, sponsored by SB Technology.
- Recruiting
- Registry status
- 150
- Enrollment target
- 2
- Study locations
NCT06481943: Recruiting study of Acute Coronary Syndrome, sponsored by SB Technology.
NCT06481943 is a study of Acute Coronary Syndrome that is actively recruiting participants, run by SB Technology. The registered enrollment target is 150 participants, below the 2,718-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06481943, a study of Acute Coronary Syndrome, is actively recruiting participants, sponsored by SB Technology.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.
Primary Outcome
Utilize linear regression and logistic regression to determine whether a set of a priori MCG-based biomarkers can prospectively predict the objective clinical assessment of ACS, while statistically adjusting for covariates.
Conditions Studied
Interventions
- DEVICE Sponsor MCG device (CardiAQ)
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2026-04 |
What NCT06481943 shows while recruiting
NCT06481943 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,718-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Sponsor MCG device (CardiAQ) is the first listed.
NCT06481943 reports a single indexed study location in Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT06481943 about?
NCT06481943 is a clinical study titled "A Prospective Research Investigation of Ischemia Using MCG". PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.
What is the current status of trial NCT06481943?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-07-11. Estimated completion is 2026-04.
What conditions does trial NCT06481943 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome.
What interventions are being tested in trial NCT06481943?
The interventions under investigation include: Sponsor MCG device (CardiAQ) (DEVICE).
Who is sponsoring clinical trial NCT06481943?
This trial is sponsored by SB Technology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06481943 being conducted?
This trial has 2 study locations across Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06481943's enrollment target sits among peer trials
150 29th of 40 higher than 11 of 40 other Acute Coronary Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Coronary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Polypill for Acute Coronary Syndrome
RECRUITING · Phase 2
-
Positive Emotions Following Acute Cardiac Events
RECRUITING · NA
-
Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock
RECRUITING
-
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
RECRUITING · Phase 3
-
AngelMed Guardian® System PMA Post Approval Study
RECRUITING
-
Online Tai Chi Plus Fitbit After ACS
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI